Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article.
- DOI
- 10.1016/j.ejca.2021.12.011
- Published
- 2022 Feb
- Container
- European journal of cancer (Oxford, England : 1990)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejca.2021.12.011,
title = {Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article.},
author = {Barrière J and Carles M and Audigier-Valette C and Re D and Adjtoutah Z and Seitz-Polski B and Gounant V and Descamps D and Zalcman G},
year = {2022},
journal = {European journal of cancer (Oxford, England : 1990)},
doi = {10.1016/j.ejca.2021.12.011},
url = {https://doi.org/10.1016/j.ejca.2021.12.011}
}RIS
TY - JOUR TI - Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article. AU - Barrière J AU - Carles M AU - Audigier-Valette C AU - Re D AU - Adjtoutah Z AU - Seitz-Polski B AU - Gounant V AU - Descamps D AU - Zalcman G PY - 2022 JO - European journal of cancer (Oxford, England : 1990) DO - 10.1016/j.ejca.2021.12.011 UR - https://doi.org/10.1016/j.ejca.2021.12.011 ER -
APA
J, B., M, C., C, A., D, R., Z, A., B, S., V, G., D, D., & G, Z. (2022). Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2021.12.011
Source records
- pubmed · retrieved 2026-09-26T21:37:00.520Z
- europe-pmc · retrieved 2026-09-26T21:37:00.531Z